Marimastat
From Wikipedia, the free encyclopedia
 |
|
|
Marimastat
|
|
| Systematic (IUPAC) name | |
| N-[2,2-dimethyl-1- (methylcarbamoyl)propyl]-2- [hydroxy-(hydroxycarbamoyl)methyl]- 4- methyl-pentanamide | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C15H29N3O5 |
| Mol. mass | 331.408 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Marimastat was a proposed matrix metalloproteinase inhibitor developed by British Biotech.
 |
This chemistry article is a stub. You can help Wikipedia by expanding it. |
